A Phase 1, Randomized, Placebo-and Positive-controlled Crossover Study To Determine The Effect Of Single-dose Pf-06700841 On Qtc Interval In Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2018
At a glance
- Drugs PF 6700841 (Primary)
- Indications Alopecia areata; Crohn's disease; Inflammatory bowel diseases; Plaque psoriasis; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Pfizer
- 28 Nov 2018 Planned End Date changed from 3 Dec 2018 to 6 Jan 2019.
- 28 Nov 2018 Planned primary completion date changed from 7 Nov 2018 to 11 Dec 2018.
- 24 Sep 2018 Status changed from not yet recruiting to recruiting.